

Docket No. UF-10293
Application Serial No. 09/780,041

3 one aberrant form of at least one gene known to be associated with said disease in
4 humans or non-human animals into appropriate tissue of a living non-human animal
5 under conditions which result in the expression of said at least one aberrant gene, wherein
6 said transferring does not require the modification of the germ-line of said living animal,
7 said composition comprising an aberrant tau gene in a vector construct which results in
8 active expression of said gene upon introduction into said tissue.

Claim 35 (new)

1 35. The composition of claim 34 wherein said aberrant tau gene is P301L, associated
2 with "fronto-temporal dementia with Parkinson's linked to chromosome 17 (FTDP-17)".

Rcmarks

Upon entry of this amendment, claims 23-35 will be before the Examiner for consideration. Claims 1-22 have been cancelled without prejudice. Applicants reserve the right to pursue any subject matter affected by this amendment in later-filed continuation and/or divisional applications. New claims 23-35 relate to provisionally elected Group 1. The language of the new claims has been amended slightly from the claims of Group 1 as originally filed to make them read more clearly.

In view of the foregoing remarks and amendments, it is respectfully urged that all claims are in a condition for allowance.

Applicant invites the Examiner to call the undersigned if clarification is needed on any aspect of this response, or if the Examiner believes that any valid basis of non-patentability remains after entrance and consideration of the remarks and amendments presented herein.

Docket No. UF-10293
Application Serial No. 09/780,041

Respectfully submitted,



Timothy H. Van Dyke
Patent Attorney
Registration No. 43,218
Phone No.: 407-228-0328
Van Dyke & Associates, P.A.
Customer Number: 29847

New Address:

7000 N. 14th Street, Suite 252